The object of this study is to present quantitative determinations of phenylalanine, tyrosine, and some of their derivatives, excreted by a two-yearold boy with clinical and urinary findings diagnostic of the rare condition known as phenylpyruvic oligophrenia. This metabolic aberration, manifested by the excretion of phenylpyruvic acid, was first described by Folling in 1934 (1) in 10 feebleminded patients, and cases have subsequently been reported by Penrose (2), Jervis (3, 4) , and others. The disease is characterized clinically by marked mental deficiency, frequently accompanied by athetosis and other neurological stigmata. Many of the patients are well-developed physically, and even attractive in appearance. Blond hair and complexion and a susceptibility to eczema are frequently observed. The incidence among institutionalized feebleminded individuals of all ages is about 0.8 per cent. On the basis of extensive genetic studies, Jervis (4) confirmed Penrose's opinion (5) that the anomaly is determined by a single autosomal recessive gene.
The quantity of phenylpyruvic acid in the urine varies with the protein intake, but even on a protein-free diet some is always excreted, derived probably from body protein. The excretion of the compound is greatly increased by the administration of phenylalanine, protein (casein), or phenylpyruvic acid, and to a lesser extent by phenyllactic acid, whereas other amino acids, including tyrosine, have no effect on its output. Thus the defect is, apparently, limited to the metabolism of phenylalanine.
REPORT OF CASE' S. W., a boy aged 25 months, was admitted on November 25, 1941 , with the chief complaints of retardation of development and eczema, after a urine specimen had given a positive, qualitative test for phenylpyruvic acid. ' We are grateful to Dr. T. D. Van Orden for the privilege of observing this patient.
The family history was positive for allergic manifestations, including hives in the father, and eczema and asthma in a brother. There was no family history of nervous illness. The only sibling, a brother, had been slow in development, having walked at 2 years of age and talked at 3, but was described by his pediatrician as entirely normal at his present age of 4. Tests of the father's, mother's, and brother's urines for phenylpyruvic acid were negative. The pregnancy was complicated by severe nausea and vomiting, and by a small pelvis which necessitated delivery by Caesarian section. The patient had been subject to a severe eczematous eruption since the age of 2 months. Mental retardation had been suspected at 4 months. The infant failed to raise his head until the age of one year, and began to take notice of his surroundings and to recognize his parents at 20 months. His first tooth erupted at 6 months. He sat without support for no more than a few minutes, and did not form words. He did not reach for objects but he seemed to take pleasure in holding a toy when it was placed in his hand.
Convulsions were never observed, but the infant was said to "jump" occasionally, with momentary flexion of the head and extension of all 4 extremities.
Physical examination revealed a large, obese, flabbymuscled, blond boy of 26 months, who could sit unsupported for a few minutes and could maintain himself on his arms and knees in a crouching position. Most of the time he lay quietly on his back. He followed a light or a large object with his eyes, and responded sluggishly to sounds. He had an attractive facies with a smiling. expression. He was goodnatured and contented most of the time, but occasionally cried and sometimes scratched his face, arms, and legs which were the sites of a dry, scaly, patchy, eczematous eruption. The child weighed 14 kilograms, and the body measurement were as follows: head circumference 46 cm., chest 55.5 cm., abdomen 54 cm., stem length 56 cm., total length 89 cm. The head appeared somewhat small in proportion to the body, but was well-formed. The fontanelles were closed. The eyes were blue, the pupils not unusual and the fundi normal. Except for moderately hyperactive deep reflexes the neurological examination was negative, and the remainder of the physical examination revealed no abnormal findings.
Roentgenograms of the skull and wrists were within normal limits. The Kline, Schick, and Mantoux tests were negative, and routine urinalyses and blood count were normal. The blood plasma ascorbic acid level which on admission was 0.7 mgm. per cent fell to 0.3 mgm. per cent after 9 (8) as recently modified by Block and Bolling (9) . The urine was acidified and extracted with ether for 24 hours in a continuous extractor. This procedure removed phenylpyruvic and phenyllactic acids which interfere with the determination of phenylalanine. Tyrosine was removed by treatment with potassium permanganate in the cold, as recommended by Kapeller-Adler (8) .
The optical isomers of phenylalanine were determined by means of the d-amino acid oxidase. The enzyme was extracted with M/60 sodium pyrophosphate solution at pH 8.0 from acetone-dried sheep kidneys, as described by Negelein and Br6mel (10) . Their more elaborate procedure ("step 1") was found unnecessary; correction for the error introduced by the small amount of acetone remaining in the kidney extract was made by a suitable blank. This enzyme converts the d-portion of d,lphenylalanine into the correspondirig keto acid (phenylpyruvic). The urine to be tested was extracted with ether to remove phenylpyruvic acid and then incubated with the enzyme for 3 hours at 37°C. Proteins were precipitated with trichloracetic acid, and phenylpyruvic acid determined in the filtrate by the dinitrophenylhydrazone method of Penrose and Quastel (lla), as modified by Sealock (llb). From the amount of phenylpyruvic acid produced, could be calculated the d-phenylalanine in the urine, and I-phenylalanine could be calculated by difference.
Jervis and his co-workers (7) have reported that phenyllactic acid gives almost as much color in the nitration process of the Kapeller-Adler method as does phenylalanine. Consequently, the method was used for the determination of phenyllactic acid as follows: To the urine was added an equal volume of saturated sodium bisulfite solution. This formed an addition compound with phenylpyruvic acid which was insoluble in ether. The urine-bisulfite mixture was then made just acid to Congo red with sulfuric acid and extracted with ether for 24 hours in a continuous extractor. The ether extract, containing phenyllactic acid, but no phenylalanine or phenylpyruvic acid, was then used for the determination of the former acid by the Kapeller-Adler method. For the purposes of this study, it appears reasonable to assume that the compound determined was actually phenyllactic acid, but complete verification must await isolation of the pure compound from the urine. If error exists, it is presumably in the direction of making the reported amounts of phenyllactic acid too high.
The Millon method as modified by Folin and Ciocalteu (12) was applied to the urine both before and after extraction with ether. Thus the total hydroxyphenyl compounds were divided into ether-soluble and ether-insoluble components.
RESULTS

Daily excretion of metabolic products
The results, calculated on the basis of 12-hour periods, are presented in Table I .
Phenylpyruvic acid. The. patient always excreted phenylpyruvic acid in amounts varying from 0.45 to 1.03 grams per 24 hours. The gradual rise in excretion during the period of observation may perhaps have been due to his higher than customary intake of protein. In adult patients on a normal diet, Jervis (13) (14)). Racemization would be consistent with the theory of Jervis and his colleagues (7) that the excess phenylalanine in the blood of phenylpyruvic oligophrenics is formed from phenylpyruvic acid, although Folling, Closs, and Gamnes (15) maintained that the excess phenyllalanine found in the blood in their cases was all the levo form. Tyrosine derivatives. The daily excretion of hydroxyphenyl compounds averaged 77 mgm. for the ether-soluble and 30 mgm. for the etherinsoluble portion. In the 5 normal subjects concerning whom other data are presented in Table  II , an average figure for the ether-insoluble fraction was 27 mgm. There is, therefore, no evidence of any abnormal excretion of hydroxyphenyl compounds in this case of phenylpyruvic oligophrenia. Effect of ingestion of tyrosine Seven and three-tenths grams l-tyrosine (0.5 gram per kgm.) was administered by mouth in a single dose without significant effect on the urinary excretion of phenylpyruvic acid or phenylalanine (Table I ). The slight increase in tyrosine and its derivatives represented roughly 2 per cent of the amount ingested and is not indicative of any fault in the metabolism of tyrosine. This confirms the results obtained by Jervis (13) . (Table III) . Within 48 hours, the extra excretion had amounted to 98 per cent of the ingested dose. 2 The maximum excretion of phenylpyruvic acid and phenylalanine was reached during the first 12 hours, whereas phenyllactic acid excretion reached its peak during the second 12 hours.
The magnitude of phenylpyruvic acid increase after phenylalanine is comparable to that observed by Penrose 87.2 * The molecular weights of these three compounds are so nearly identical that calculations of percentages or sums of percentages are the same whether reported "as phenylpyruvic acid," "as phenyllactic acid' or "as phenylalanine." t Diet unchanged except for ingestion of 0.4 gram ascorbic acid daily.
The high excretion of phenylalanine, both before and particularly after the ingestion of this substance, was in contrast to the observation of Jervis (13) who found none at all in the urine of a phenylpyruvic oligophrenic, even after administering phenylalanine by mouth. F6lling, Gloss, and Gamnes (15) , using a qualitative method, reported that an increased excretion of phenylalanine followed the oral or intravenous administration of d-phenylalanine to their human subjects.
It is interesting to note that only about 6 per -cent of the ingested d,l-phenylalanine was excreted as the 1-isomer, whereas 13 to 25 per cent of it was excreted as d-phenylalanine. Presumably the body excreted more of the unnatural enantiomorph which is less readily metabolized.
Effect of ascorbic acid Because vitamin C has been shown to prevent or relieve a defect in the metabolism of tyrosine and phenylalanine exhibited by premature infants (16), it was tested in this case of phenylpyruvic oligophrenia (Tables I and III) . It was completely without effect in relieving the spontaneous phenylketonuria and did not prevent the increased excretion of the metabolic products of phenylalanine after the administration of the amino acid. It is unlikely that the small differences in the rate and pattern of excretion of the derivatives in the two sets of observations following phenylalanine ingestion are attributable to ingested ascorbic acid. Jervis (17) found similar results in his patients.
DISCUSSION
The path of normal metabolism of phenylalanine is still a matter of speculation. Presumably, it is first deaminized to form the -keto acid, phenylpyruvic acid, which may then be completely oxidized. There is, however, evidence that at least some phenylalanine may be converted in the body to tyrosine or its metabolic products, p-hydroxyphenylpyruvic and p-hydroxyphenyllactic acids (18) . In phenylpyruvic oligophrenia, there is apparently no impairment in the metabolism of tyrosine. Even after the administration of tyrosine or phenylalanine there is no significant increase in urinary excretion of substances giving the Millon reaction. This finding, taken in conjunction with the fact that ingested phenylalanine can be accounted for almost quantitatively as excess phenylpyruvic and phenyllactic acids and phenylalanine, would indicate that phenylpyruvic oligophrenics do not metabolize phenylalanine by way of tyrosine. It is interesting to speculate whether tyrosine, which is not considered an essential amino acid in normal individuals, may be essential in these cases. If patients with phenylpyruvic oligophrenia are unable to form tyrosine from phenylalanine or its metabolic products, then they must be dependent on a dietary intake of tyrosine for their metabolic needs of this amino acid.
Undoubtedly, phenylalanine is deaminized to phenylpyruvic acid, but the mechanism and site of this deamination are still uncertain. If it takes place chiefly in the liver, one would expect to find phenylpyruvic acid in the blood in the process of transportation to the kidneys. Both Folling, Closs, and Gamnes (15) and Jervis and his colleagues (7) were unable to find significant amounts of phenylpyruvic acid in the blood of their patients, but they did find abnormally large amounts of phenylalanine in the blood. Jervis concluded that the essential defect of the subjects is an inability to dispose of phenylalanine at a normal rate rather than a failure to break down phenylpyruvic acid, as had been previously assumed. The presence of phenylpyruvic acid in the urine he considered to be an incidental phenomenon, resulting from the deamination of a portion of the blood phenylalanine by kidney tissue. The excretion by our subject; S. W., of large amounts of phenylalanine after ingestion of this substance may have been due to the size of the dose given (7.4 grams, 0.5 gram per kgm. of body weight), which was much greater than that which Jervis (13) administered to his patient. The amounts of phenylalanine in the urine of S. W. were of the same order of magnitude as those found in normal infants given comparable doses (18) . The latter, however, never exhibited the most striking metabolic characteristic of the phenylpyruvic oligophrenic, namely, the excretion of significant amounts of phenylpyruvic acid, and they did, in the absence of vitamin C, show evidence of conversion of phenylalanine to tyrosine which was not observed in the oligophrenic subject.
The clinical value of the qualitative test for phenylpyruvic acid in the urine of infants suspected of mental retardation should be emphasized. The test should be applied especially in those retarded children who are blond in coloring, and whose mental deficiency is suspected on the basis of slowness in acquiring behavior patterns and yet seems to be belied by an attractive facial appearance. The presence of eczema, of a family history positive for mental deficiency, or of neurological manifestations characteristic of extrapyramidal tract involvement, should also lead to a suspicion of this disease, though their absence does not rule it out. 4. The administration of 1-tyrosine in similar dosage (0.5 gram per kgm.) had no significant effect on the excretion of phenylpyruvic acid, nor was there any evidence of an abnormality in the metabolism of tyrosine.
5. The administration of large doses of ascorbic acid (0.4 gram per day) had no effect, either on the spontaneous excretion of phenylpyruvic acid or on the increased excretion of metabolic products following the ingestion of phenylalanine. 6 . The absence in the urine of significant amounts of hydroxyphenyl compounds in this patient, spontaneously and even after the ingestion of phenylalanine, suggests that the conversion in vivo of phenylalanine to tyrosine, previously shown to take place in the normal organism, is deficient in patients with phenylpyruvic oligophrenia. This finding is consistent with the thesis advanced by Jervis and his coworkers (7) that in this disease the primary metabolic defect is an inability to handle phenylalanine.
